腹膜癌广泛转移症（PC）被认为是一种病情末期，存活时间短的疾病。其通过姑息疗法治疗，包括反复引流和化疗注入。自上世纪九十年代以来，手术已与更有效的全身化疗、腹膜腔化疗和高温腹腔灌注化疗（HIPEC）联合治疗PC。这种联合疗法极大地增加了选定的PC患者的总体生存率。目前人们对于腹腔腔内化疗和HIPEC如何治愈患者的理解尚不太清楚。专家们猜测高腹腔药物暴露和高温作用直接杀死癌细胞的能力是有效的。几项研究表明癌细胞死亡直接影响免疫系统的反应。因此，腹腔腔内化疗和HIPEC的保护作用可能通过其用免疫原性的方式杀死癌细胞以引起有效的抗癌免疫反应。在本文中，我们研究先天性腹膜或局部治疗诱导的免疫反应在PC治疗中的作用。版权所有© 2022 Elsevier Inc.

Peritoneal Carcinomatosis (PC) is considered as a terminal disease with short survival. It is treated with palliative therapies, consisting of repeated drainages and sometimes instillation of chemotherapy. Since the nineties, surgery has been combined with more effective systemic chemotherapy, intraperitoneal chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of PC. This combination therapy significantly increases the overall survival of selected PC patients. The understanding of how intraperitoneal chemotherapy and HIPEC can cure patients is still unclear. Experts hypothesized that the efficacy is obtained by the ability of high peritoneal drug exposure and hyperthermia to directly kill cancer cells. Several studies indicate that cancer cells death directly influences the response of the immune system. For this reason, the protective effect of intraperitoneal chemotherapy and HIPEC could be mediated by its ability to kill cancer cells in an immuno-genic way, causing an efficient anticancer immune response. In this review, we investigate the role of the innate peritoneal or locoregional therapy-induced immune response in PC therapy.Copyright © 2022 Elsevier Inc. All rights reserved.